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artery stenosis do better with open endarterectomy (CEA)
than with less invasive stenting (CAS). Or do they?
Long-term results from the International Carotid Stenting
Study (ICSS), the largest trial comparing these procedures,
were presented recently at the European Stroke Conference
in London. Previous differences in peri-procedural non-
disabling outcome events had favoured CEA; now, after
median follow-up of 4 years, both procedures have similar
long-term disability, quality of life and restenosis rates.1e3
When the Asymptomatic Carotid Surgery Trial (ACST)
compared contemporary medical treatment (CMT) with
CMT and CEA, CEA halved 5-year stroke risk, and the 6e7%
absolute stroke risk reduction was maintained to 10
years.4,5 As most CEAs are carried out for asymptomatic
stenosis (ACS), with the aim of reducing future stroke risk, it
is important to determine whether CAS can be similarly
effective.
Large registries and the Carotid Revascularisation Endar-
terectomy versus Stenting Trial (CREST) have demonstrated
that CAS may be an acceptable alternative to CEA in
asymptomatic patients without morphological limitations
(such as circumferential calciﬁcation, for example).6,7 Stroke
risk is similar but there is no incision and cranial nerve injury
is unlikely. With increasing operator experience, CAS may
also have become safer.
This issue includes a report on the ﬁrst 700 ACS patients
enrolled in the Second Asymptomatic Carotid Surgery Trial
(ACST-2), a randomised trial comparing CAS and CEA.8 As
the trial will continue for some years, this paper describes
blinded results only. Peri-procedural disabling stroke and
death rate for both groups was 1.0%. In the previous ACST,
CEA caused disabling stroke and death in 1.7% patients,
before beneﬁt became apparent later. ACST-2 patients are
generally older and more are diabetic. So, is improved CAS
experience leading to improving results?
A pooled randomised trial analysis by the Carotid
Stenosis Trialists’ Collaboration (CSTC) found that peri-
procedural risk for CAS fell when collaborators’ volume of
work increased, a ﬁnding also shown by large European
registries.9DOI of original article: http://dx.doi.org/10.1016/j.ejvs.2013.07.020
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http://dx.doi.org/10.1016/j.ejvs.2013.07.019As a patient with ACS, which procedure would you prefer,
if revascularisation was indicated and there were no long-
term differences between CAS and CEA? Probably CAS,
but convincing evidence is needed before practice can
change. ACST-2 plans to address this need.
What differences will this make to European health? At
least 1 million Europeans have ACS, and are at higher
than normal risk of heart attack and stroke.10 Intervention
rates in Europe vary greatly between countries, and the
proportion of people without recent symptoms having
these procedures also varies (around 60% in Germany
and Italy, 50% in France, and 15% in UK and Sweden).
Screening is not advocated, except prior to cardiac
bypass, but if ACS is discovered, the appropriate course of
action is often unclear. About half of strokes caused by
bypass surgery are thought to be caused by ACS, but prior
intervention with CEA or CAS is not clearly indicated.11 If
trials should show CAS to be as effective as CEA, this
could provide a less invasive means of stroke prevention
prior to CABG, and would be welcomed by patients and
surgeons.
It is important for patients to enter trials; they will
generally get better treatment and closer monitoring, and a
trial will protect them from biased treatment, even one
with a fairly low risk. The care they receive should aim to
reduce their vascular risk effectively for at least the next 10
years.
Three other trials address a different, equally important
question: does intervention by CEA or CAS offer additional
beneﬁt over CMT alone in patients with ACS not presumed
to be at high risk of stroke? The second Stent-Protected
Angioplasty versus Carotid Endarterectomy trial (SPACE-2)
has redesigned its protocol into two separate trials, SPACE
2a and 2b. If collaborator and patient prefer stenting, SPACE
2a compares CMT alone with CAS and CMT; if CEA is
preferred, SPACE 2b compares CMT alone with CEA and
CMT.12 In North America, CREST-2 will employ a comparable
design, as does the second European Carotid Surgery Trial
(ESCT-2) studying patients with carotid stenosis at low or
intermediate risk of stroke with or without previous
symptoms.13
So, when the need for intervention is uncertain, enrol in
SPACE-2, CREST-2 or ECST-2 but when intervention is
thought necessary, ACST-2 remains the only trial directly
comparing CAS versus CEA.
Collaborators should be encouraged to join both types of
studies, allowing more patients the opportunity to partici-
pate. Governments increasingly recognize that trials are a
necessary and welcome part of patient choice and good
L.H. Bonati and H.-H. Eckstein 509practice, making healthcare more affordable by improving
evidence.
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